Join Free For Buyer|Sign In

Professional Online Trade Platform for API, Preparation and Pharmaceutical Machinery and Equipment_EN-CPhI.cn

You are here:  Home >>  News >>  Policy & Regulation >>  FDA updates on voluntary valsartan recalls

FDA updates on voluntary valsartan recalls

November 26, 2018 By europeanpharmaceuticalreview
Tag: FDA , valsartan , recalls

In August this year, drugs with valsartan as the active ingredient were recalled because of the presence of NMDA.

FDA updates on voluntary valsartan recalls

These angiotensin II receptor blockers (ARBs) are used to treat people with high blood pressure and heart failure.

Many healthcare professionals and patients were warned by the US Food and Drug Administration of the voluntary recall, because of the impurity, N-nitrosodimethylamine (NMDA), being a known human carcinogen.

After this voluntary recall, the FDA has continually updated its list of both recalled pharmaceutical drugs, and products that are not currently under recall, with the company details and details of the drug being recalled.

In October, the FDA published laboratory results of an investigation looking into the recalled products, and identifying levels of NMDA. Despite the recalls, the FDA also mentioned how the risk was low; stating that if 8,000 people took the highest valsartan dose containing NDMA from the recalled batches daily for four years, there may be one additional case of cancer over the lifetimes of the 8,000 people. 

With this estimate being based on the highest daily dose of valsartan (320 miligrams), and many taking lower than this, the FDA stated that theoretically the risk of cancer to most patients should then be lower than this estimation.

The FDA published a gas chromatography-mass spectrometry (GC/MS) headspace method for regulators and manufacturers to detect and quantify NMDA in valsartan API and in completed drug products. The organisation also published gas chromatography-tandem mass spectrometry (GC-MS/MS) method that utilised liquid injection to detect the presence of the impurity in varsartan drug products, which can be used alone or in tandem with the initial method.

In doing so, the FDA reminded manufacturers that it is their responsibility to develop and use suitable methods to detect impurities, especially when they make changes to their manufacturing processes.

Should a higher level or new impurity be detected, then it should be fully evaluated before being offered to patients.

A series of questions and answers are also available on the FDA’s website, for further insights into these recalls.

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.

 

Readers'Comments
Add a comment
Click here to Login or to Register for free. You will be taken back to your selected item after Login/Registration.
More>> MarketNews
More>> Editors’Picks
More>> TopStories
More>> HotTags
Follow Us
CPhI Online Trade Platform: Worldwide|English|中国站
Customer Service:  86-400 610 1188 (9: 00-18: 00, Mon-Fri)
About Us| Contact Us| Terms of Services| Privacy Policy| Intellectual Property Statement| Links | Site Map
Copyright 2006-20 Shanghai UBM Sinoexpo International Exhibition Co Ltd (All Rights Reserved). ICP 05034851-53
网页对话
live chat